Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL

[41] Glasziou P(2012)Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients Thromb Haemost 107 1053-65

[42] van Walraven C(1999)Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 927-34

[43] Jennings A(2003)American Heart Association/American College of Cardiology Foundation guide to warfarin therapy Circulation 107 1692-711

[44] Oake N(2012)Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial Circulation 126 2309-16

[45] Fergusson D(2010)Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study J Thromb Haemost 8 101-6

[46] Forster AJ(2008)An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage J Thromb Haemost 6 935-43

[47] Connolly SJ(2014)Concerns over data in key dabigatran trial BMJ 349 g4747-undefined

[48] Ezekowitz MD(2014)Dabigatran: how the drug company withheld important analyses BMJ 349 g4670-undefined

[49] Yusuf S(2014)Dabigatran, bleeding, and the regulators BMJ 349 g4517-undefined

[50] Eikelboom J(undefined)undefined undefined undefined undefined-undefined

[41] Glasziou P(2012)Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients Thromb Haemost 107 1053-65

[42] van Walraven C(1999)Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 927-34

[43] Jennings A(2003)American Heart Association/American College of Cardiology Foundation guide to warfarin therapy Circulation 107 1692-711

[44] Oake N(2012)Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial Circulation 126 2309-16

[45] Fergusson D(2010)Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study J Thromb Haemost 8 101-6

[46] Forster AJ(2008)An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage J Thromb Haemost 6 935-43

[47] Connolly SJ(2014)Concerns over data in key dabigatran trial BMJ 349 g4747-undefined

[48] Ezekowitz MD(2014)Dabigatran: how the drug company withheld important analyses BMJ 349 g4670-undefined

[49] Yusuf S(2014)Dabigatran, bleeding, and the regulators BMJ 349 g4517-undefined

[50] Eikelboom J(undefined)undefined undefined undefined undefined-undefined